Blogs & Articles

GPI thought-leadership, pricing and market access insights. Our blogs, white papers and resources provide the latest strategic insight.

LATEST BLOGS / ARTICLES

FDA deals significant blow to low-priced Chinese oncology drugs

FDA rejects application for sintilimab in combination with chemotherapy, to deal blow to Eli Lilly and creating additional challenges for low-priced Chinese oncology drugs in the US market.